Brokerages forecast that BioScrip Inc (NASDAQ:BIOS) will post sales of $171.79 million for the current quarter, Zacks reports. Four analysts have provided estimates for BioScrip’s earnings, with the highest sales estimate coming in at $173.40 million and the lowest estimate coming in at $170.49 million. BioScrip reported sales of $240.12 million in the same quarter last year, which indicates a negative year over year growth rate of 28.5%. The business is scheduled to issue its next quarterly earnings report on Friday, March 2nd.
On average, analysts expect that BioScrip will report full year sales of $171.79 million for the current year, with estimates ranging from $805.10 million to $808.00 million. For the next financial year, analysts expect that the company will post sales of $722.13 million per share, with estimates ranging from $695.23 million to $734.93 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for BioScrip.
BIOS has been the subject of a number of analyst reports. SunTrust Banks reaffirmed a “buy” rating and issued a $3.00 target price on shares of BioScrip in a research report on Friday, November 3rd. Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. ValuEngine raised shares of BioScrip from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, BidaskClub raised shares of BioScrip from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $3.63.
BioScrip (BIOS) traded down $0.09 during trading on Monday, reaching $2.89. 829,500 shares of the company were exchanged, compared to its average volume of 908,189. The company has a market capitalization of $380.00, a P/E ratio of -4.25 and a beta of 0.19. BioScrip has a 1-year low of $1.35 and a 1-year high of $3.39. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.